Natco Pharma Receives Tentative Approval for Erdafitinib Tablets
Natco Pharma received tentative FDA approval for its generic Erdafitinib tablets. The drug, a generic of Balversa®, had U.S. sales of approximately USD 60 million for the 12 months ending September 2025. This marks a significant step in expanding Natco's oncology portfolio in the U.S. market.
The tentative approval for a generic drug that had significant previous sales represents a positive step for Natco Pharma, potentially leading to increased revenue and market share in the oncology segment. However, it is tentative approval, and the full impact depends on final approval and market launch.
The tentative approval for a generic drug, especially one with substantial market sales, is a positive development for the company, indicating potential future revenue and market penetration.
Natco Pharma Limited has received tentative approval for its generic version of Erdafitinib tablets, a drug indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma. The approval covers 3 mg, 4 mg, and 5 mg dosages. Erdafitinib tablets, a generic of Balversa®, had estimated sales of approximately USD 60 million in the U.S. for the 12 months ending September 2025, according to industry sales data.
Erdafitinib is prescribed for patients with disease progression during at least one line of prior therapy and who harbor susceptible FGFR3 genetic alterations. The announcement was made via a press release filed with the BSE and NSE on February 3, 2026.
Natco Pharma Limited, headquartered in Hyderabad, India, is an R&D-driven pharmaceutical company with a strong focus on oncology and limited competition molecules in the U.S. market. The company operates nine manufacturing sites and two R&D facilities in India, with several facilities approved by major regulatory authorities like the U.S. FDA, Brazil ANVISA, and Health Canada.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.